File(s) under permanent embargo
Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief
journal contributionposted on 24.11.2022, 03:07 authored by Oliver MasseyOliver Massey, Cenk SuphiogluCenk Suphioglu
Interleukin 5 (IL-5) is a major cytokine responsible for eosinophil proliferation, migration and degranulation. Eosinophils play a considerable role in the manifestation of type 2 asthma, and therefore this makes IL-5 a unique and clinically important target for therapeutic intervention. Due to the critical role that IL-5 plays in all areas of eosinophil activity, it has been identified and targeted by three therapeutics, Mepolizumab, Benralizumab and Reslizumab. This review describes the IL-5 pathway and presents the clinical trial history of the three IL-5 inhibitors, to provide insight into the role of IL-5 in clinical asthma presentation. Additionally, this review aims to foster further investigation into the IL-5 pathway by describing current novel therapeutic discovery strategies with monoclonal antibodies.
JournalInternational Journal of Molecular Sciences
Publication classificationC1 Refereed article in a scholarly journal
Read the peer-reviewed publication
ALPHA MONOCLONAL-ANTIBODYasthmaBenralizumabBENRALIZUMABBiochemistry & Molecular BiologyChemistryChemistry, MultidisciplinaryDOUBLE-BLINDeosinophilic inflammationHYPEREOSINOPHILIC SYNDROMEIL-5 RECEPTOR-ALPHAimmunotherapyInterleukin-5Life Sciences & BiomedicineMepolizumabMEPOLIZUMABOPEN-LABELPhysical SciencesPLACEBOQUALITY-OF-LIFEReslizumabScience & TechnologySEVERE EOSINOPHILIC ASTHMAAnti-Asthmatic AgentsAntibodies, MonoclonalAsthmaEosinophilsHumansLeukocyte CountClinical ResearchLungClinical Trials and Supportive ActivitiesBiotechnologyRespiratorySchool of Life and Environmental SciencesInstitute for Innovation in Mental and Physical Health and Clinical TranslationFaculty of Science Engineering and Built Environment